Which has preferable valuation & earnings, ABUS or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arbutus Biopharma $14.08M 62.43 -$33.50M $0.83 5.36 Telix Pharmaceuticals $803.79M 4.31 -$7.12M N/A N/A

Which has better earnings & valuation, ABUS or ALMS?

Arbutus Biopharma has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arbutus Biopharma $14.08M 62.43 -$33.50M $0.83 5.36 Alumis $8.40M 371.91 -$243.32M -$1.98 N/A

Is ABUS or ALMS more profitable?

Arbutus Biopharma has a net margin of 83.95% compared to Alumis' net margin of -2,825.70%. Arbutus Biopharma's return on equity of 129.32% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Arbutus Biopharma 83.95% 129.32% 112.24% Alumis -2,825.70% -88.79% -70.72%

Arbutus Biopharma (ABUS) Competitors

$4.45 -0.07 (-1.55%)

Closing price 06/23/2026 04:00 PM Eastern

Extended Trading

$4.50 +0.04 (+1.01%)

As of 06/23/2026 07:26 PM Eastern

Compare

ABUS vs. VKTX, TLX, ALMS, GPCR, and ARQT

Should you buy Arbutus Biopharma stock or one of its competitors? MarketBeat compares Arbutus Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arbutus Biopharma include Viking Therapeutics (VKTX), Telix Pharmaceuticals (TLX), Alumis (ALMS), Structure Therapeutics (GPCR), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "pharmaceutical products" industry.

How does Arbutus Biopharma compare to Viking Therapeutics?

Viking Therapeutics (NASDAQ:VKTX) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

76.0% of Viking Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 5.3% of Viking Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Viking Therapeutics has a beta of 0.69, meaning that its share price is 31% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Viking Therapeutics currently has a consensus price target of $93.60, indicating a potential upside of 168.89%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 12.36%. Given Viking Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viking Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.79
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Viking Therapeutics had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Viking Therapeutics and 0 mentions for Arbutus Biopharma. Viking Therapeutics' average media sentiment score of 0.46 beat Arbutus Biopharma's score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Viking Therapeutics	Neutral
Arbutus Biopharma	Neutral

Arbutus Biopharma has a net margin of 83.95% compared to Viking Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Viking Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viking Therapeutics	N/A	-71.31%	-65.35%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arbutus Biopharma has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viking Therapeutics	N/A	N/A	-$359.64M	-$4.14	N/A
Arbutus Biopharma	$14.08M	62.43	-$33.50M	$0.83	5.36

Summary

Viking Therapeutics and Arbutus Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Arbutus Biopharma (NASDAQ:ABUS) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

Telix Pharmaceuticals has higher revenue and earnings than Arbutus Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.43	-$33.50M	$0.83	5.36
Telix Pharmaceuticals	$803.79M	4.31	-$7.12M	N/A	N/A

Arbutus Biopharma presently has a consensus target price of $5.00, indicating a potential upside of 12.36%. Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 106.90%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Arbutus Biopharma has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.11, meaning that its share price is 111% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 4 more articles in the media than Arbutus Biopharma. MarketBeat recorded 4 mentions for Telix Pharmaceuticals and 0 mentions for Arbutus Biopharma. Telix Pharmaceuticals' average media sentiment score of 0.44 beat Arbutus Biopharma's score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Arbutus Biopharma	Neutral
Telix Pharmaceuticals	Neutral

Arbutus Biopharma has a net margin of 83.95% compared to Telix Pharmaceuticals' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Telix Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Telix Pharmaceuticals	N/A	N/A	N/A

43.8% of Arbutus Biopharma shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Telix Pharmaceuticals beats Arbutus Biopharma on 8 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Alumis?

Arbutus Biopharma (NASDAQ:ABUS) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, risk, profitability, institutional ownership, media sentiment, valuation, earnings and analyst recommendations.

43.8% of Arbutus Biopharma shares are owned by institutional investors. 19.9% of Arbutus Biopharma shares are owned by company insiders. Comparatively, 33.7% of Alumis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	62.43	-$33.50M	$0.83	5.36
Alumis	$8.40M	371.91	-$243.32M	-$1.98	N/A

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 12.36%. Alumis has a consensus price target of $40.30, indicating a potential upside of 64.42%. Given Alumis' stronger consensus rating and higher possible upside, analysts plainly believe Alumis is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Arbutus Biopharma's average media sentiment score of 0.00 equaled Alumis'average media sentiment score.

Company	Overall Sentiment
Arbutus Biopharma	Neutral
Alumis	Neutral

Arbutus Biopharma has a net margin of 83.95% compared to Alumis' net margin of -2,825.70%. Arbutus Biopharma's return on equity of 129.32% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	83.95%	129.32%	112.24%
Alumis	-2,825.70%	-88.79%	-70.72%

Arbutus Biopharma has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market. Comparatively, Alumis has a beta of -0.55, meaning that its share price is 155% less volatile than the broader market.

Summary

Arbutus Biopharma beats Alumis on 9 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, valuation, risk, earnings, media sentiment and institutional ownership.

Structure Therapeutics presently has a consensus target price of $110.55, indicating a potential upside of 142.37%. Arbutus Biopharma has a consensus target price of $5.00, indicating a potential upside of 12.36%. Given Structure Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Structure Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 5.5% of Structure Therapeutics shares are held by company insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Structure Therapeutics has a beta of -1.35, suggesting that its share price is 235% less volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, suggesting that its share price is 37% less volatile than the broader market.

In the previous week, Structure Therapeutics had 2 more articles in the media than Arbutus Biopharma. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Arbutus Biopharma. Structure Therapeutics' average media sentiment score of 0.00 equaled Arbutus Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Structure Therapeutics	Neutral
Arbutus Biopharma	Neutral

Arbutus Biopharma has a net margin of 83.95% compared to Structure Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 129.32% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arbutus Biopharma has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Arbutus Biopharma	$14.08M	62.43	-$33.50M	$0.83	5.36

Summary

Arbutus Biopharma beats Structure Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Arbutus Biopharma compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Arbutus Biopharma (NASDAQ:ABUS) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

In the previous week, Arcutis Biotherapeutics had 8 more articles in the media than Arbutus Biopharma. MarketBeat recorded 8 mentions for Arcutis Biotherapeutics and 0 mentions for Arbutus Biopharma. Arcutis Biotherapeutics' average media sentiment score of 0.48 beat Arbutus Biopharma's score of 0.00 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Arcutis Biotherapeutics	Neutral
Arbutus Biopharma	Neutral

Arcutis Biotherapeutics has higher revenue and earnings than Arbutus Biopharma. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$376.07M	8.74	-$16.14M	-$0.03	N/A
Arbutus Biopharma	$14.08M	62.43	-$33.50M	$0.83	5.36

Arbutus Biopharma has a net margin of 83.95% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arbutus Biopharma's return on equity of 129.32% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Arbutus Biopharma	83.95%	129.32%	112.24%

Arcutis Biotherapeutics currently has a consensus price target of $34.00, indicating a potential upside of 29.43%. Arbutus Biopharma has a consensus price target of $5.00, indicating a potential upside of 12.36%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Arcutis Biotherapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Arbutus Biopharma	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arcutis Biotherapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Comparatively, Arbutus Biopharma has a beta of 0.63, suggesting that its stock price is 37% less volatile than the broader market.

43.8% of Arbutus Biopharma shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 19.9% of Arbutus Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Arcutis Biotherapeutics and Arbutus Biopharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Arbutus Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABUS vs. The Competition

Export

Metric	Arbutus Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$892.87M	$3.45B	$6.45B	$12.39B
Dividend Yield	N/A	2.30%	2.69%	5.83%
P/E Ratio	5.36	19.75	24.92	23.98
Price / Sales	62.43	330.90	528.23	109.07
Price / Cash	N/A	128.56	44.82	54.51
Price / Book	11.13	8.29	10.79	6.50
Net Income	-$33.50M	$23.85M	$3.56B	$336.88M
7 Day Performance	0.45%	2.87%	1.00%	-0.14%
1 Month Performance	2.30%	2.19%	0.42%	0.77%
1 Year Performance	32.05%	55.48%	29.70%	28.49%

Arbutus Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABUS Arbutus Biopharma	1.2371 of 5 stars	$4.45 -1.5%	$5.00 +12.4%	+30.5%	$892.87M	$14.08M	5.36	90
VKTX Viking Therapeutics	2.5438 of 5 stars	$29.63 +3.1%	$93.60 +215.9%	+40.0%	$3.34B	N/A	N/A	20	Options Volume
TLX Telix Pharmaceuticals	4.1618 of 5 stars	$9.54 -0.2%	$21.13 +121.4%	-37.7%	$3.24B	$803.79M	N/A	1,184	News Coverage Positive News
ALMS Alumis	2.3872 of 5 stars	$23.00 -4.8%	$40.30 +75.2%	+775.4%	$3.08B	$24.05M	N/A	N/A	Gap Down
GPCR Structure Therapeutics	2.2105 of 5 stars	$43.07 +0.3%	$106.75 +147.9%	+106.4%	$3.05B	N/A	N/A	136

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABUS) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arbutus Biopharma (ABUS) Competitors

ABUS vs. VKTX, TLX, ALMS, GPCR, and ARQT

How does Arbutus Biopharma compare to Viking Therapeutics?

Summary

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Summary

How does Arbutus Biopharma compare to Alumis?

Summary

How does Arbutus Biopharma compare to Structure Therapeutics?

Summary

How does Arbutus Biopharma compare to Arcutis Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arbutus Biopharma (ABUS) Competitors

ABUS vs. VKTX, TLX, ALMS, GPCR, and ARQT

How does Arbutus Biopharma compare to Viking Therapeutics?

Do institutionals and insiders hold more shares of VKTX or ABUS?

Which has more volatility and risk, VKTX or ABUS?

Do analysts prefer VKTX or ABUS?

Does the media favor VKTX or ABUS?

Is VKTX or ABUS more profitable?

Which has better earnings & valuation, VKTX or ABUS?

Summary

How does Arbutus Biopharma compare to Telix Pharmaceuticals?

Which has preferable valuation & earnings, ABUS or TLX?

Do analysts rate ABUS or TLX?

Which has more volatility & risk, ABUS or TLX?

Does the media favor ABUS or TLX?

Is ABUS or TLX more profitable?

Do institutionals & insiders hold more shares of ABUS or TLX?

Summary

How does Arbutus Biopharma compare to Alumis?

Do insiders & institutionals believe in ABUS or ALMS?

Which has better earnings & valuation, ABUS or ALMS?

Do analysts recommend ABUS or ALMS?

Does the media refer more to ABUS or ALMS?

Is ABUS or ALMS more profitable?

Which has more risk & volatility, ABUS or ALMS?

Summary

How does Arbutus Biopharma compare to Structure Therapeutics?

Do analysts rate GPCR or ABUS?

Do insiders and institutionals believe in GPCR or ABUS?

Which has more volatility and risk, GPCR or ABUS?

Does the media prefer GPCR or ABUS?

Is GPCR or ABUS more profitable?

Which has preferable earnings & valuation, GPCR or ABUS?

Summary

How does Arbutus Biopharma compare to Arcutis Biotherapeutics?

Does the media prefer ARQT or ABUS?

Which has stronger valuation & earnings, ARQT or ABUS?

Is ARQT or ABUS more profitable?

Do analysts rate ARQT or ABUS?

Which has more risk & volatility, ARQT or ABUS?

Do institutionals & insiders believe in ARQT or ABUS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABUS vs. The Competition

Arbutus Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools